Phase 2a, Exploratory, Double-blind, Placebo-controlled Two-part Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Topically Applied XPF-002 (XEN402 8% w/w Ointment) in Patients With Primary/Inherited Erythromelalgia.
Phase of Trial: Phase I/II
Latest Information Update: 05 Jun 2014
At a glance
- Drugs Funapide (Primary)
- Indications Erythromelalgia
- Focus Therapeutic Use
- Sponsors Xenon Pharmaceuticals
- 05 Jun 2012 Actual patient number added 8 according to ClinicalTrials.gov.
- 05 Jun 2012 Actual end date (May 2012) added as reported by ClinicalTrials.gov.
- 05 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.